Initial Deutetrabenazine Compliance, Satisfaction, and Patient Perception of Change in Huntington Disease Symptoms (P4.040)

Objective: To examine medication satisfaction, adherence, and patient perception of change in overall symptoms of Huntington disease (HD) 90 days after deutetrabenazine treatment initiation compared with baseline. Background: Deutetrabenazine is approved for the treatment of chorea associated with HD in the United States (Austedo™ approved on April 3, 2017). Shared Solutions ® (ShS) is a Teva support program designed to support the needs of HD patients, their care partners, and healthcare professionals prescribing deutetrabenazine. Design/Methods: All patients in this prospective data collection were enrolled in the ShS program between April and July 2017 for at least 90 days. Patient-reported medication satisfaction was measured using the Medication Satisfaction Questionnaire. Adherence or compliance data were collected using the Morisky Medication Adherence Scale. Similar to the randomized, double-blind, Phase III study, First-HD, the perception of change in overall symptoms was assessed using the Patient Global Impression of Change. De-identified patient data and data fields from ShS were extracted and analyzed. Statistical analysis was descriptive only (frequency, percentage, mean/median, standard deviation, and range, as appropriate). Results: 291 HD patients (43% male, 57% female) met inclusion criteria. The average age of patients was 56.9 years. 56% of patients had government-issued insurance. Overall, 65% of patients were “very satisfied” or “extremely satisfied” with deutetrabenazine. Patients with HD showed high adherence (88%) to deutetrabenazine therapy. 51% of the patients reported “much improved” or “very much improved” in their HD symptoms overall. Conclusions: High levels of medication adherence and treatment satisfaction were demonstrated in HD patients receiving deutetrabenazine therapy in a real-world setting with more than half of the patients reporting improvement in overall HD symptoms in the first 90 days after initiation of deutetrabenazine. The findings in this study reinforced the findings in the First-HD clinical trial. Study Supported by: This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel. Disclosure: Dr. Sung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva. Dr. Iyer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Abler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Bibeau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Claassen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Neuroscience, Lundbeck, Acadia, AbbVie. Dr. Claassen has received research support from NIH/NINDS, Michael J. Fox Foundation, Huntington Disease Society of America, Vaccinex, AbbVie, Auspex Pharmaceuticals. Dr. Frank has received research support from Teva Pharmaceutical Industries.